The RBD antigen of SARS-CoV-2 producing yeast strain from Texas Children’s Hospital / Baylor College of Medicine was used by Biological E Limited, India to develop & manufacture CORBEVAX®, the COVID-19 vaccine and approximately 100 million doses have been administered to people in IndiaHOUSTON, Jan. 22, 2024 /PRNewswire/ — Texas Children’s Hospital announces today that Biological E’s CORBEVAX®, a traditional, recombinant protein-based COVID-19 vaccine has received World Health Organization (WHO) approval under Emergency Use Listing (EUL). CORBEVAX® is developed and commercialized by Biological E Limited, an established global vaccine supplier based in Hyderabad, India, using Pichia pastoris yeast strain expressing Receptor Binding…